Name: Latest research reports of Zydus Lifesciences Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: Phillip Capital

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer

927.5500 -3.50 (-0.38%)

NSE Jan 07, 2026 15:31 PM

Volume: 518.1K

Zydus Lifesciences Ltd.

16 May 2016

927.55

-0.38%

Cadila Q4FY16 Update 16May2016

Buy: Zydus Lifesciences Ltd.

Recommendation

Phillip Capital

9 JV business saw strong 25%/14% growth for Q4/FY16. However, it guides for flattish revenueperformancefromitsJVbusinessinFY17 9 CDHindicatestocompletelargepartofremedialactionsbyMay2016atitsproblematic...

Number of FII/FPI investors decreased from 707 to 682 in Dec 2025 qtr